Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Reports 2004 First Quarter Results
Dynavax Reports 2004 First Quarter Results BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious
View HTML
Toggle Summary Dynavax Reports 2003 Fourth Quarter and Full Year Results
Dynavax Reports 2003 Fourth Quarter and Full Year Results BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML
Toggle Summary /C O R R E C T I O N -- Dynavax Technologies Corporation/
/C O R R E C T I O N -- Dynavax Technologies Corporation/ In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated
View HTML
Toggle Summary Dynavax Full Year and Fourth Quarter Earnings Conference Call
Dynavax Full Year and Fourth Quarter Earnings Conference Call BERKELEY, Calif., March 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML
Toggle Summary Dynavax Names Denise M. Gilbert to Board of Directors
Dynavax Names Denise M. Gilbert to Board of Directors BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit
View HTML
Toggle Summary Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer
Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer BERKELEY, Calif., March 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of D. Kevin Kwok, Pharm.D., to the position of vice president and chief business officer.
View HTML
Toggle Summary Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy
Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the start of a
View HTML
Toggle Summary Dynavax Announces Exercise of Underwriters' Over-Allotment Option
Dynavax Announces Exercise of Underwriters' Over-Allotment Option BERKELEY, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that the underwriters of its previously announced initial public offering of 6,000,000 shares of common stock have
View HTML
Toggle Summary Dynavax Prices IPO at $7.50 Per Share
Dynavax Prices IPO at $7.50 Per Share BERKELEY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it has priced its initial public offering of 6,000,000 shares of its common stock at $7.50 per share, below the estimated range.
View HTML
Toggle Summary Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products
Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products Berkeley, CA - February 5, 2004 - Dynavax Technologies Corporation announced today that it has entered into an agreement with UCB Pharma, the pharmaceuticals division
View HTML